Mode
Text Size
Log in / Sign up

Report describes colorectal cancer screening prevalence by age, demographics, and state in the US

Report describes colorectal cancer screening prevalence by age, demographics, and state in the US
Photo by Navy Medicine / Unsplash
Key Takeaway
Note descriptive report on US CRC screening prevalence by demographics and state.

A descriptive report provides information on colorectal cancer screening test use within the United States population. The report's primary outcome is current colorectal cancer screening prevalence. It notes that colorectal cancer is the second leading cause of cancer death in the US.

The main findings describe current colorectal cancer screening prevalence by age, various demographic factors, and by state. No specific intervention, comparator, sample size, or follow-up duration is reported. The report does not provide effect sizes, absolute numbers, p-values, or confidence intervals for the described prevalence patterns.

No safety, tolerability, or adverse event data are reported, as this is not an interventional study. Key methodological details such as study phase, funding sources, and potential conflicts of interest are not reported. The report's limitations are not explicitly stated.

This report offers a descriptive, cross-sectional look at screening patterns. It does not establish causality or test the effectiveness of any specific screening intervention. The findings are relevant for understanding the current landscape of colorectal cancer screening utilization across different populations and geographies in the US.

Study Details

EvidenceLevel 5
PublishedMar 2020
View Original Abstract ↓
Of cancers that affect both men and women, colorectal cancer (CRC) is the second leading cause of cancer death in the United States. This report describes current CRC screening prevalence by age, various demographic factors, and state.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.